Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2012

01-12-2012 | NON-THEMATIC REVIEW

Cancer stem cells, microRNAs, and therapeutic strategies including natural products

Authors: Darshni Vira, Saroj K. Basak, Mysore S. Veena, Marilene B. Wang, Raj K. Batra, Eri S. Srivatsan

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Login to get access

Abstract

Embryonic stem cells divide continuously and differentiate into organs through the expression of specific transcription factors at specific time periods. Differentiated adult stem cells on the other hand remain in quiescent state and divide by receiving cues from the environment (extracellular matrix or niche), as in the case of wound healing from tissue injury or inflammation. Similarly, it is believed that cancer stem cells (CSCs), forming a smaller fraction of the tumor bulk, also remain in a quiescent state. These cells are capable of initiating and propagating neoplastic growth upon receiving environmental cues, such as overexpression of growth factors, cytokines, and chemokines. Candidate CSCs express distinct biomarkers that can be utilized for their identification and isolation. This review focuses on the known and candidate cancer stem cell markers identified in various solid tumors and the promising future of disease management and therapy targeted at these markers. The review also provides details on the differential expression of microRNAs (miRNAs), and the miRNA- and natural product-based therapies that could be applied for the treatment of cancer stem cells.
Literature
1.
Croker, A. K., & Allan, A. L. (2008). Cancer stem cells: implications for the progression and treatment of metastatic disease. Journal of Cellular and Molecular Medicine, 12, 374–390.PubMed
2.
Felthaus, O., Ettl, T., Gosau, M., Driemel, O., Brockhoff, G., Reck, A., et al. (2011). Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochemical and Biophysical Research Communications, 407, 28–33.PubMed
3.
Ganguli-Indra, G., Wasylyk, C., Liang, X., Millon, R., Leid, M., Wasylyk, B., et al. (2009). CTIP2 expression in human head and neck squamous cell carcinoma is linked to poorly differentiated tumor status. PLoS One, 4, e5367.PubMed
4.
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: models and concepts. Annual Review of Medicine, 58, 267–284.PubMed
5.
Boman, B. M., & Huang, E. (2008). Human colon cancer stem cells: a new paradigm in gastrointestinal oncologyogy. Journal of Clinical Oncologyogy, 26, 2828–2838.
6.
Jagani, Z., & Khosravi-Far, R. (2008). Cancer stem cells and impaired apoptosis. Advances in Experimental Medicine and Biology, 615, 331–344.PubMed
7.
Joshua, B., Kaplan, M. J., Doweck, I., Pai, R., Weissman, R., Prince, M., et al. (2012). Frequency of cells expressing CD 44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head & Neck, 34, 42–49.
8.
Bhaijee, F., Pepper, D. J., Pitman, K. T., & Bell, D. (2012). Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications. Head & Neck, 34, 894–899.
9.
Graziano, A., d’ Aquino, R., Tirino, V., Desiderio, V., Rossi, A., & Pirozzi, G. (2008). The stem cell hypothesis in head and neck cancer. Journal of Cellular Biochemistry, 103, 408–412.PubMed
10.
Jensen, K. B., Jones, J., & Watt, F. M. (2008). A stem cell gene expression profile of human squamous cell carcinomas. Cancer Letters, 272, 23–31.PubMed
11.
Harper, L. J., Piper, K., Common, J., Fortune, F., & Mackenzie, I. C. (2007). Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 36, 594–603.PubMed
12.
Sayed, S. I., Dwivedi, R. C., Katna, R., Garg, A., Pathak, K. A., Nutting, C. M., et al. (2011). Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncology, 47, 237–243.PubMed
13.
Shakib, K., Schrattenholz, A., & Soskic, V. (2011). Stem cells in head and neck squamous cell carcinoma. British Journal of Oral and Maxillofacial Surgery, 49, 503–506.PubMed
14.
Adams, J. M., Kelly, P. N., Dakic, A., Carotta, S., Nutt, S. L., & Strasser, A. (2008). Role of “cancer stem cells” and cell survival in tumor development and maintenance. Cold Spring Harbor Symposia on Quantitative Biology, 73, 451–459.PubMed
15.
Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea—a paradigm shift. Cancer Research, 66, 1883–1896.PubMed
16.
Ailles, L., & Prince, M. (2009). Cancer stem cells in head and neck squamous cell carcinoma. Methods in Molecular Biology, 568, 175–193.PubMed
17.
Albers, A. E., Chen, C., Köberle, B., Qian, X., Klussmann, J. P., Wollenberg, B., et al. (2012). Stem cells in squamous head and neck cancer. Critical Reviews in Oncology/Hematology, 81, 224–240.PubMed
18.
Chen, Z. G. (2009). The cancer stem cell concept in progression of head and neck cancer. Journal of Oncology, 2009, 894064.PubMed
19.
Furusawa, J., Zhang, H., Vural, E., Stone, A., Fukuda, S., Oridate, N., et al. (2011). Distinct epigenetic profiling in head and neck squamous cell carcinoma stem cells. Otolaryngology and Head and Neck Surgery, 144, 900–909.
20.
Akhtar, K., Bussen, W., & Scott, S. P. (2009). Cancer stem cells - from initiation to elimination, how far have we reached? International Journal of Oncology, 34, 1491–1503.PubMed
21.
Al-Ejeh, F., Smart, C. E., Morrison, B. J., Chenevix-Trench, G., Lopez, J. A., Lakhani, S. R., et al. (2011). Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis, 32, 650–658.PubMed
22.
Clarke, M. F. (2005). Epigenetic regulation of normal and cancer stem cells. Annals of the New York Academy of Sciences, 1044, 90–93.PubMed
23.
McDermott, S. P., & Wicha, M. S. (2010). Targeting breast cancer stem cells. Molecular Oncology, 4, 404–419.PubMed
24.
Bapat, S. A. (2007). Evolution of cancer stem cells. Seminars in Cancer Biology, 17, 204–213.PubMed
25.
Bleau, A.-M., Huse, J. T., & Holland, E. C. (2009). The ABCG2 resistance network of glioblastoma. Cell Cycle, 8, 2936–2944.PubMed
26.
Garvalov, B. K., & Acker, T. (2011). Cancer stem cells: a new framework for the design of tumor therapies. Journal of Molecular Medicine, 89, 95–107.PubMed
27.
Spillane, J. B., & Henderson, M. A. (2007). Cancer stem cells: a review. ANZ Journal of Surgery, 77, 464–468.PubMed
28.
Bonnet, D., & Dick, J. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730–737.PubMed
29.
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature, 367, 645–648.PubMed
30.
Dick, J. (2005). Acute myeloid leukemia stem cells. Annals of the New York Academy of Sciences, 1044, 1–5.PubMed
31.
Dick, J. (2008). Stem cell concepts renew cancer research. Blood, 112, 4793–4807.PubMed
32.
Houghton, J., Morozov, A., Smirnova, I., & Wang, T. C. (2007). Stem cells and cancer. Seminars in Cancer Biology, 17, 191–203.PubMed
33.
Bonnet, D. (2005). Cancer stem cells: AMLs show the way. Biochemical Society Transactions, 33, 1531–1533.PubMed
34.
Bonnet, D. (2005). Cancer stem cells: lessons from leukemia. Cell Proliferation, 38, 357–361.PubMed
35.
Schatton, T., Frank, N. Y., & Frank, M. H. (2009). Identification and targeting of cancer stem cells. Bioessays, 31, 1038–1049.PubMed
36.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988.PubMed
37.
Dontu, G., Al-Hajj, M., Abdallah, W. M., Clarke, M. F., & Wicha, M. S. (2003). Stem cells in normal breast development and breast cancer. Cell Proliferation, 36, 59–72.PubMed
38.
Basak, S., Veena, M. S., Oh, S., Huang, G., Srivatsan, E. S., Huang, M., et al. (2009). The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One, 4, e5884.PubMed
39.
Ailles, L. E., & Weissman, I. L. (2007). Cancer stem cells in solid tumors. Current Opinion in Biotechnology, 18, 460–466.PubMed
40.
Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104, 973–978.PubMed
41.
Baumann, M., & Krause, M. (2010). CD 44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clinical Cancer Research, 16, 5091–5093.PubMed
42.
Pries, R., Witrkopf, N., Trenkle, T., Nitsch, S. M., & Wollenberg, B. (2008). Potential stem cell marker CD 44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo, 22, 89–92.PubMed
43.
Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I., & Clarke, M. F. (2004). Therapeutic implications of cancer stem cells. Current Opinion in Genetics & Development, 14, 43–47.
44.
Chan, K. S., Volkmer, J.-P., & Weissman, I. (2010). Cancer stem cells in bladder cancer: a revisited and evolving concept. Current Opinion in Urology, 20, 393–397.PubMed
45.
Chen, S. Y., Huang, Y. C., Liu, S. P., Tsai, F. J. L., Shyu, W. C., & Lin, S. Z. (2011). An overview of concepts for cancer stem cells. Cell Transplantation, 20, 113–120.PubMed
46.
Cho, R. W., & Clarke, M. F. (2008). Recent advances in cancer stem cells. Current Opinion in Genetics & Development, 18, 48–53.
47.
Diehn, M., Cho, R. W., & Clarke, M. F. (2009). Therapeutic implications of the cancer stem cell hypothesis. Seminars in Radiation Oncology, 19, 78–86.PubMed
48.
Hollier, B. G., Evans, K., & Mani, S. A. (2009). The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia, 14, 29–43.PubMed
49.
Almhanna, K., & Philip, P. A. (2011). Defining new paradigms for the treatment of pancreatic cancer. Current Treatment Options in Oncology, 12, 111–125.PubMed
50.
Deonarain, M. P., Kousparou, C. A., & Epenetos, A. A. (2009). Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs, 1, 12–25.PubMed
51.
Dimov, I., Visnjic, M., & Stefanovic, V. (2010). Urothelial cancer stem cells. The Scientific World Journal, 10, 1400–1415.
52.
Vries, R. G. J., Huch, M., & Clevers, H. (2010). Stem cells and cancer of the stomach and intestine. Molecular Oncology, 4, 373–384.PubMed
53.
Gedye, C., Davidson, A. J., Elmes, M. R., Cebon, J., Bolton, D., & David, I. D. (2010). Cancer stem cells in urologic cancers. Urologic Oncology, 28, 585–590.PubMed
54.
Okamoto, A., Chikamatsu, K., Sakakura, K., Hatsushika, K., Takahashi, G., & Masuyama, K. (2009). Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncology, 45, 633–639.PubMed
55.
Kokko, L. L., Hurme, S., Maula, S. M., Alanen, K., Grenman, R., Kinnunen, I., et al. (2011). Significance of site-specific prognosis of cancer stem cell marker CD 44 in head and neck squamous-cell carcinoma. Oral Oncology, 47, 510–516.PubMed
56.
Chikamatsu, K., Takahashi, G., Sakakura, K., Ferrone, S., & Masuyama, K. (2011). Immunoregulatory properties of CD 44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head & Neck, 33, 208–215.
57.
Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., et al. (2010). Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Science, 101, 293–299.PubMed
58.
Sarkar, F. H., Li, Y., Wang, Z., & Kong, D. (2009). Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chirurgica, 64, 489–500.PubMed
59.
Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29, 4741–4751.PubMed
60.
Davis, S. J., Divi, V., Owen, J. H., Bradford, C. R., Carey, T. E., Papagerakis, S., et al. (2010). Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Archives of Otolaryngology-Head & Neck Surgery, 136, 1260–1266.
61.
Chen, C., Wei, Y., Hummel, M., Hoffmann, T. K., Gross, M., Kaufmann, A. M., et al. (2011). Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One, 6, e16466.PubMed
62.
Mack, B., & Gires, O. (2008). CD 44s and CD 44v6 expression in head and neck epithelia. PLoS One, 3, e3360.PubMed
63.
Jijiwa, M., Demir, H., Gupta, S., Leung, C., Joshi, K., Orozco, N., et al. (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One, 6, e24217.PubMed
64.
Gaviraghi, M., Tunici, P., Valensin, S., Rossi, M., Giordano, C., Magnoni, L., et al. (2011). Pancreatic cancer sphere are more than just aggregates of stem marker-positive cells. Bioscience Reports, 31, 45–55.PubMed
65.
Nilsson, S. K., Johnston, H. M., Whitty, G. A., Williams, B., Webb, R. J., Denhardt, D. T., et al. (2005). Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood, 106, 1232–1239.PubMed
66.
van den Hoogen, C., van der Horst, G., Cheung, H., Buijs, J. T., Pelger, R. C., & van der Pluijm, G. (2011). The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clinical and Experimental Matastasis, 28, 615–625.
67.
Prince, M. E. P., & Ailles, L. E. (2008). Cancer stem cells in head and neck squamous cell cancer. Journal of Clinical Oncology, 26, 2871–2875.PubMed
68.
Chen, H., Zhou, L., Dou, T., Wan, G., Tang, H., & Tian, J. (2011). BMI1’S maintenance of the proliferative capacity of laryngeal cancer stem cells. Head & Neck, 33, 1115–1125.
69.
Zhou, L., Wei, X., Cheng, L., Tian, J., & Jiang, J. J. (2007). CD 133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope, 117, 455–460.PubMed
70.
Monroe, M. M., Anderson, E. C., Clayburgh, D. R., & Wong, M. H. (2011). Cancer stem cells in head and neck squamous cell carcinoma. Journal of Oncology, 2011, 762780.PubMed
71.
Zhang, Q., Shi, S., Yen, Y., Brown, J., Ta, J. Q., & Le, A. D. (2010). A subpopulation of CD 133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Letters, 289, 151–160.PubMed
72.
Ricci-Vitiani, L., Fabrizi, E., Palio, E., & De Maria, R. (2009). Colon cancer stem cells. Journal of Molecular Medicine, 87, 1097–1104.PubMed
73.
Hubbard, S. A., & Gargett, C. E. (2010). A cancer stem cell origin for human endometrial carcinoma? Reproduction, 140, 23–32.PubMed
74.
Zhang, J., Luo, N., Luo, Y., Peng, Z., Zhang, T., & Li, S. (2011). MicroRNA-150 inhibits human CD 133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. International Journal of Oncology, 40, 747–756.PubMed
75.
Eramo, A., Haas, T. L., & De Maria, R. (2010). Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene, 29, 4625–4635.PubMed
76.
O’Brien, C. A., Kreso, A., & Dick, J. (2009). Cancer stem cells in solid tumors: an overview. Seminars in Radiation Oncology, 19, 71–77.PubMed
77.
O’Brien, C. A., Kreso, A., & Jamieson, C. H. M. (2010). Cancer stem cells and self-renewal. Clinical Cancer Research, 16, 3113–3120.PubMed
78.
Bednar, F., & Simeone, D. M. (2009). Pancreatic cancer stem cells and relevance to cancer treatments. Journal of Cellular Biochemistry, 107, 40–45.PubMed
79.
Dunning, N. L., Laversin, S. A., Miles, A. K., & Rees, R. C. (2011). Immunotherapy of prostate cancer: should we be targeting stem cells and EMT? Cancer Immunology, Immunotherapy, 60, 1181–1193.PubMed
80.
Yang, J.-P., Liu, Y., Zhong, W., Yu, D., Wen, L. J., & Jin, C. S. (2011). Chemo resistance of CD 133+ cancer stem cells in laryngeal carcinoma. Chinese Medical Journal, 124, 1055–1060.PubMed
81.
Zhang, H., Li, W., Nan, F., Ren, F., Wang, H., Xu, Y., et al. (2011). MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochemical and Biophysical Research Communications, 404, 273–278.PubMed
82.
Alison, M. R., Islam, S., & Wright, N. A. (2010). Stem cells in cancer: instigators and propagators? Journal of Cell Science, 123, 2357–2368.PubMed
83.
Padhye, S. S., Guin, S., Yao, H. P., Zhou, Y. Q., Zhang, R., & Wang, M. H. (2011). Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Molecular Pharmaceutics, 8, 2310–2319.PubMed
84.
Lonardo, E., Hermann, P. C., & Heeschen, C. (2010). Pancreatic cancer stem cells—update and future perspectives. Molecular Oncology, 4, 431–442.PubMed
85.
Lee, C. J., Dosch, J., & Simeone, D. M. (2008). Pancreatic cancer stem cells. Journal of Clinical Oncology, 26, 2806–2812.PubMed
86.
Soltanian, S., & Matin, M. M. (2011). Cancer stem cells and cancer therapy. Tumour Biology, 32, 425–440.PubMed
87.
Miyoshi, N., Ishii, H., Sekimoto, M., Haraguchi, N., Doki, Y., & Mori, M. (2010). Properties and identification of cancer stem cells: a changing insight into intractable cancer. Surgery Today, 40, 608–613.PubMed
88.
Zhou, J., & Zhang, Y. (2008). Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle, 7, 1360–1370.PubMed
89.
Richard, V., & Pillai, M. R. (2010). The stem cell code in oral epithelial tumorigenesis: “the cancer stem cell shift hypothesis. Biochimica et Biophysica Acta, 1806, 146–162.PubMed
90.
Mishra, L., Banker, T., Murray, J., Byers, S., Thenappan, A., He, A. R., et al. (2009). Liver stem cells and hepatocellular carcinoma. Hepatology, 49, 318–329.PubMed
91.
Yao, Z., & Mishra, L. (2009). Cancer stem cells and hepatocellular carcinoma. Cancer Biology & Therapy, 8, 1691–1698.
92.
Yi, S. Y., & Nan, K. J. (2008). Tumor-initiating stem cells in liver cancer. Cancer Biology & Therapy, 7, 325–330.
93.
Oishi, N., & Wang, X. W. (2011). Novel therapeutic strategies for targeting liver cancer stem cells. International Journal of Biological Sciences, 7, 517–535.PubMed
94.
Sell, S., & Leffert, H. L. (2008). Liver cancer stem cells. Journal of Clinical Oncology, 26, 2800–2805.PubMed
95.
Sales, K. M., Winslet, M. C., & Seifalian, A. M. (2007). Stem cells and cancer: an overview. Stem Cell Review and Reports, 3, 249–255.
96.
Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nature Medicine, 17, 313–319.PubMed
97.
Bussolati, B., Bruno, S., Grange, C., Ferrando, U., & Camussi, G. (2008). Identification of a tumor-initiating stem cell population in human renal carcinomas. The FASEB Journal, 22, 3696–3705.
98.
Alison, M. R., Lim, S. M. L., & Nicholson, L. J. (2011). Cancer stem cells: problems for therapy? The Journal of Pathology, 223, 147–161.PubMed
99.
Lee, T. K. W., Castilho, A., Ma, S., & Ng, I. O. L. (2009). Liver cancer stem cells: implications for a new therapeutic target. Liver International, 29, 955–965.PubMed
100.
Chen, Y. C., Chen, Y. W., Hsu, H. S., Tseng, L. M., Huang, P. I., Lu, K. H., et al. (2009). Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochemical and Biophysical Research Communications, 385, 307–313.PubMed
101.
Chen, Y. C., Chang, C. J., Hsu, H. S., Chen, Y. W., Tai, L. K., Tsengm, L. M., et al. (2010). Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncology, 46, 158–165.PubMed
102.
Alison, M. R., Guppy, N. J., Lim, S. M. L., & Nicholson, L. J. (2010). Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? The Journal of Pathology, 222, 335–344.PubMed
103.
Visus, C., Ito, D., Amoscato, A., Maciejewska-Franczak, M., Abdelsalem, A., Dhir, R., et al. (2007). Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Research, 67, 10538–10545.PubMed
104.
Huang, E. H., Hynes, M. J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., et al. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 69, 3382–3389.PubMed
105.
Douville, J., Beaulieu, R., & Balicki, D. (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells and Development, 18, 17–25.PubMed
106.
Keysar, S. B., & Jimeno, A. (2010). More than markers: biological significance of cancer stem cell-defining molecules. Molecular Cancer Therapeutics, 9, 2450–2457.PubMed
107.
Lawson, J. C., Blatch, G. L., & Edkins, A. L. (2009). Cancer stem cells in breast cancer and metastasis. Breast Cancer Research and Treatment, 118, 241–254.PubMed
108.
Ma, I., & Allan, A. L. (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Reviews, 7, 292–306.PubMed
109.
Ohi, Y., Umekita, Y., Yoshioka, T., Souda, M., Rai, Y., Sagara, Y., et al. (2011). Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology, 59, 776–780.PubMed
110.
Subramaniam, D., Ramalingam, S., Houchen, C. W., & Anant, S. (2010). Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Reviews in Medicinal Chemistry, 10, 359–371.PubMed
111.
Sullivan, J. P., Minna, J., & Shay, J. W. (2010). Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Reviews, 29, 61–72.PubMed
112.
Clay, M. R., Tabor, M., Owen, J., Carey, T. E., Bradford, C. R., Wolf, G. T., et al. (2010). Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head & Neck, 32, 1195–1201.
113.
Krishnamurthy, S., Dong, Z., Vodopyanov, D., Imai, A., Helman, J., Prince, M. E., et al. (2010). Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Research, 70, 9969–9978.PubMed
114.
Gupta, V., & Bamezai, R. N. K. (2010). Human pyruvate kinase M2: a multifunctional protein. Protein Science, 19, 2031–2044.PubMed
115.
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J. K., Shen, M., et al. (2011). Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science, 334, 1278–1283.PubMed
116.
Mazurek, S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry & Cell Biology, 43, 969–980.
117.
Hathurusinghe, H. R., Goonetilleke, K. S., & Siriwardena, A. K. (2007). Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Annals of Surgical Oncology, 14, 2714–2720.PubMed
118.
Rayess, H., Wang, M. B., & Srivatsan, E. S. (2012). Cellular senescence and tumor suppressor gene p16. International Journal of Cancer, 130, 1715–1725.
119.
Yu, C. C., Lo, W. L., Chen, Y. W., Huang, P. I., Hsu, H. S., Tseng, L. M., et al. (2011). Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. Journal of Oncology. doi:10.​1155/​2011/​609259
120.
Hermann, P. C., Bhaskar, S., Cioffi, M., & Heeschen, C. (2010). Cancer stem cells in solid tumors. Seminars in Cancer Biology, 20, 77–84.PubMed
121.
Ouyang, G., Wang, Z., Fang, X., Liu, J., & Yang, C. J. (2010). Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cellular and Molecular Life Sciences, 67, 2605–2618.PubMed
122.
Reiman, J. M., Knutson, K. L., & Radisky, D. C. (2010). Immune promotion of epithelial–mesenchymal transition and generation of breast cancer stem cells. Cancer Research, 70, 3005–3008.PubMed
123.
Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial mesenchymal transitions. Nature Reviews Molecular Cell Biology, 7, 131–142.PubMed
124.
Cakouros, D., Raices, R. M., Gronthos, S., & Glackin, C. A. (2010). Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification/differentiation and tumorigenesis. Journal of Cellular Biochemistry, 110, 1288–1298.PubMed
125.
Yang, M. H., Hsu, D. S. S., Wang, H. W., Wang, H. J., Lan, H. Y., Yang, W. H., et al. (2010). Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nature Cell Biology, 12, 982–992.PubMed
126.
Cheng, L., Bao, S., & Rich, J. N. (2010). Potential therapeutic implications of cancer stem cells in glioblastoma. Biochemistry & Pharmacology, 80, 654–665.
127.
Sun, S., & Wang, Z. (2011). Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. International Journal of Cancer, 129, 2337–2348.
128.
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. The Journal of Experimental Medicine, 183, 1797–1806.PubMed
129.
Wu, C., Wei, Q., Utomo, V., Nadesan, P., Whetstone, H., Kandel, R., et al. (2007). Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Research, 67, 8216–8222.PubMed
130.
Song, J., Chang, I., Chen, Z., Kang, M., & Wang, C. Y. (2010). Characterization of side populations in HNSCC: highly invasive, chemo resistant and abnormal Wnt signaling. PLoS One, 5, e11456.PubMed
131.
Sun, G., Fujii, M., Sonoda, A., Tokumaru, Y., Matsunaga, T., & Habu, N. (2010). Identification of stem-like cells in head and neck cancer cell lines. Anticancer Research, 30, 2005–2010.PubMed
132.
Tabor, M. H., Clay, M. R., Owen, J. H., Bradford, C. R., Carey, T. E., Wolf, G. T., et al. (2011). Head and neck cancer stem cells: the side population. Laryngoscope, 121, 527–533.PubMed
133.
Ozvegy-Laczka, C., Cserepes, J., Elkind, N. B., & Sarkadi, B. (2005). Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resistance Updates, 8, 15–26.PubMed
134.
Zhang, P., Zhang, Y., Mao, L., Zhang, Z., & Chen, W. (2009). Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Letters, 277, 227–234.PubMed
135.
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–111.PubMed
136.
Bapat, S. A. (2010). Human ovarian cancer stem cells. Reproduction, 140, 33–41.PubMed
137.
Kim, C. F., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 121, 823–835.PubMed
138.
Ding, X-wei, Wu, J-hua, & Jiang, C-ping. (2010). ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sciences, 86, 631–637.PubMed
139.
Fong, M. Y., & Kakar, S. S. (2010). The role of cancer stem cells and the side population in epithelial ovarian cancer. Histology and Histopathology, 25, 113–120.PubMed
140.
Kratz, J. R., Yagui-Beltrán, A., & Jablons, D. M. (2010). Cancer stem cells in lung tumorigenesis. The Annals of Thoracic Surgery, 89, S2090–S2095.PubMed
141.
Kyo, S., Maida, Y., & Inoue, M. (2011). Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer Letters, 308, 123–133.PubMed
142.
Moserle, L., Ghisi, M., Amadori, A., & Indraccolo, S. (2010). Side population and cancer stem cells: therapeutic implications. Cancer Letters, 288, 1–9.PubMed
143.
Lavon, I., Zrihan, D., Granit, A., Einstein, O., Fainstein, N., Cohen, M. A., et al. (2010). Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro-Oncology, 12, 422–433.PubMed
144.
Yu, X. F., Zou, J., Bao, Z. J., & Dong, J. (2011). miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World Journal of Gastroenterology, 42, 4711–4717.
145.
Shi, L., Zhang, J., Pan, T., Zhou, J., Gong, W., Liu, N., et al. (2010). MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Research, 1312, 120–126.PubMed
146.
Schraivogel, D., Weinmann, L., Beier, D., Tabatabai, G., Eichner, A., Zhu, J. Y., et al. (2011). CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO Journal, 30, 4309–4322.PubMed
147.
Gal, H., Pandi, G., Kanner, A. A., Ram, Z., Lithwick-Yanai, G., Amariglio, N., et al. (2008). MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochemical and Biophysical Research Communications, 376, 86–90.PubMed
148.
Ji, J., & Wang, X. W. (2012). Identification of cancer stem cell-related microRNAs in hepatocellular carcinoma. Methods in Molecular Biology, 826, 163–175.PubMed
149.
Jung, C. J., Iyengar, S., Blahnik, K. R., Ajuha, T. P., Jiang, J. X., Farnham, P. J., et al. (2011). Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One, 6, 27740.
150.
Meng, F., Glaser, S. S., Francis, H., Demorrow, S., Han, Y., Passarini, J. D., et al. (2012). Functional analysis of microRNAs in human hepatocellular cancer stem cells. Journal of Cellular and Molecular Medicine, 16, 160–173.PubMed
151.
Ma, S., Tang, K. H., Chan, Y. P., Lee, T. K., Kwan, P. S., Castilho, A., et al. (2010). miR-130b Promotes CD 133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell, 7, 694–707.PubMed
152.
Jung, D. E., Wen, J., Oh, T., & Song, S. Y. (2011). Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas, 40, 1180–1187.PubMed
153.
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., et al. (2009). MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One, 4, e6816.PubMed
154.
Yu, F., Jiao, Y., Zhu, Y., Wang, Y., Zhu, J., Cui, X., et al. (2012). MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial–mesenchymal transition in breast tumor-initiating cells. Journal of Biological Chemistry, 287, 465–473.PubMed
155.
Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., et al. (2011). Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clinical Cancer Research, 17, 7105–7115.PubMed
156.
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109–1123.PubMed
157.
Zhang, X., Wan, G., Mlotshwa, S., Vance, V., Berger, F. G., Chen, H., et al. (2010). Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Research, 70, 7176–7186.PubMed
158.
Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., Qian, D., et al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 138, 592–603.PubMed
159.
Leung, M., Rosen, D., Fields, S., Cesano, A., & Budman, D. R. (2011). Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Molecular Medicine, 17, 854–862.PubMed
160.
Mukhopadhyay, A., Curtin, N., Plummer, R., & Edmondson, R. J. (2011). PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalized medicine. British Journal of Obstetrics and Gynaecology, 118, 429–432.PubMed
161.
Alexander, B. M., Wang, X. Z., Niemierko, A., Weaver, D. T., Mak, R. H., Roof, K. S., et al. (2012). DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. International Journal of Radiation Oncology and Biological Physics, 83, 164–171.
162.
Kemp, Z., & Jones, A. (2011). A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Advances in Therapy, 28, 603–614.PubMed
163.
Javle, M., & Curtin, N. J. (2011). The role of PARP in DNA repair and its therapeutic exploitation. British Journal of Cancer, 105, 1114–1122.PubMed
164.
Weil, M. K., & Chen, A. P. (2011). PARP inhibitor treatment in ovarian and breast cancer. Current Problems in Cancer, 35, 7–50.PubMed
165.
O’Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., et al. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. The New England Journal of Medicine, 364, 205–214.PubMed
166.
Barreto-Andrade, J. C., Efimova, E. V., Mauceri, H. J., Beckett, M. A., Sutton, H. G., Darga, T. E., et al. (2011). Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Molecular Cancer Therapeutics, 10, 1185–1193.PubMed
167.
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., et al. (2012). Phase II, Open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology, 30, 372–379.PubMed
168.
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews. Drug Discovery, 10, 868–880.PubMed
169.
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011). Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncology, 6, 17–27.PubMed
170.
Russell, R. C., Fang, C., & Guan, K. L. (2011). An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development, 138, 3343–3356.PubMed
171.
Fang, L., Barekati, Z., Zhang, B., Liu, Z., & Zhong, X. (2011). Targeted therapy in breast cancer: what’s new? Swiss Medical Weekly, 141, w13231.PubMed
172.
Kudo, M. (2011). Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Digestive Diseases, 29, 273–277.PubMed
173.
Liao, Y. M., Kim, C., & Yen, Y. (2011). Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head & Neck Oncology, 3, 22.
174.
Pal, S. K., & Figlin, R. A. (2011). Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Targeted Oncology, 6, 5–16.PubMed
175.
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364, 514–523.PubMed
176.
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148–1154.PubMed
177.
Voss, M. H., Molina, A. M., & Motzer, R. J. (2011). mTOR inhibitors in advanced renal cell carcinoma. Hematology/Oncology Clinics of North America, 25, 835–852.PubMed
178.
Leonard, G. D., Fojo, T., & Bates, S. E. (2003). The role of ABC transporters in clinical practice. The Oncologist, 8, 411–424.PubMed
179.
Binello, E., & Germano, I. M. (2011). Targeting glioma stem cells: a novel framework for brain tumors. Cancer Science, 102, 1958–1966.PubMed
180.
Ahmed-Belkacem, A., Pozza, A., Macalou, S., Perez-Victoria, J. M., Boumendjel, A., & Di Pietro, A. (2006). Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anti-Cancer Drugs, 17, 239–243.PubMed
181.
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L., et al. (2001). Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology, 19, 2975–2982.PubMed
182.
Seiden, M. V., Swenerton, K. D., Matulonis, U., Campos, S., Rose, P., Batist, G., et al. (2002). A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecologic Oncology, 86, 302–310.PubMed
183.
Fang, J., Seki, T., & Maeda, H. (2009). Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Advanced Drug Delivery Reviews, 61, 290–302.PubMed
184.
Wang, Z., Wang, M., Kar, S., & Carr, B. I. (2009). Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition. Journal of Cellular Physiology, 221, 213–220.PubMed
185.
Kosakowska-Cholody, T., Cholody, W. M., Hariprakasha, H. K., Monks, A., Kar, S., Wang, M., et al. (2009). Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemotherpy and Pharmacology, 63, 769–778.
186.
Nelson, E. A., Sharma, S. V., Settleman, J., & Frank, D. A. (2011). A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget, 2, 518–524.
187.
Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., et al. (2011). Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Human Molecular Genetics, 20, 4143–4154.PubMed
188.
Yamaki, H., Nakajima, M., Shimotohno, K. W., & Tanaka, N. (2011). Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. Journal of Antibiotics, 64, 635–644.PubMed
189.
Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., et al. (2011). Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research, 17, 5132–5139.PubMed
190.
Rajan, A., Kelly, R. J., Trepel, J. B., Kim, Y. S., Alarcon, S. V., Kummar, S., et al. (2011). A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clinical Cancer Research, 17, 6831–6839.PubMed
191.
Basak, S., Pookot, D., Noonan, E. J., & Dahiya, R. (2008). Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Molecular Cancer Therapeutics, 7, 3195–4202.PubMed
192.
Stühmer, T., Zöllinger, A., Siegmund, D., Chatterjee, M., Grella, E., Knop, S., et al. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia, 22, 1604–1612.PubMed
193.
Terasaki, M., Sugita, Y., Arakawa, F., Okada, Y., Ohshima, K., & Shigemori, M. (2011). CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathology, 28, 89–97.PubMed
194.
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011). CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clinical Cancer Research, 17, 2074–2080.PubMed
195.
Singh, B., Cook, K. R., Martin, C., Huang, E. H., Mosalpuria, K., Krishnamurthy, S., et al. (2010). Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clinical & Experimental Metastasis, 27, 233–240.
196.
Ray, P., Lewin, S. A., Mihalko, L. A., Schmidt, B. T., Luker, K. E., & Luker, G. D. (2011). Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia, 13, 1152–1161.PubMed
197.
Dunn, K. L., Espino, P. S., Drobic, B., He, S., & Davie, J. R. (2005). The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochemistry and Cell Biology, 83, 1–14.PubMed
198.
Tanaka, S., & Arii, S. (2011). Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. Journal of Gastroenterology, 46, 289–296.PubMed
199.
Bhoori, S., Toffanin, S., Sposito, C., Germini, A., Pellegrinelli, A., Lampis, A., et al. (2010). Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. Journal of Hepatology, 52, 771–775.PubMed
200.
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., et al. (2011). Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129, 245–255.
201.
Lewis, C. M., Glisson, B. S., Feng, L., Wan, F., Tang, X., Wistuba, I. I., et al. (2012). A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clinical Cancer Research, 18, 1435–1446.PubMed
202.
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 13, 239–246.PubMed
203.
Schønnemann, K. R., Yilmaz, M., Bjerregaard, J. K., Nielsen, K. M., & Pfeiffer, P. (2012). Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. European Journal of Cancer, 48, 510–517.PubMed
204.
Ha, H. T., Griffith, K. A., Zalupski, M. M., Schuetze, S. M., Thomas, D. G., Lucas, D. R., et al. (2012). Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma. American Journal Clinical Oncology, (in press).
205.
Sarkar, F. H., Li, Y., Wang, Z., Kong, D., & Ali, S. (2010). Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resistance Updates, 3, 57–66.
206.
Yang, Y. P., Chien, Y., Chiou, G. Y., Cherng, J. Y., Wang, M. L., Lo, W. L., et al. (2012). Inhibition of cancer stem cell-like properties and reduced chemo-radio resistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials, 33, 1462–1476.PubMed
207.
Dubrovska, A., Elliott, J., Salamone, R. J., Kim, S., Aimone, L. J., Walker, J. R., et al. (2010). Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clinical Cancer Research, 16, 5692–5702.PubMed
208.
Clarke, J. D., Dashwood, R. H., & Ho, E. (2008). Multi-targeted prevention of cancer by sulforaphane. Cancer Letters, 269, 291–304.PubMed
209.
Wilken, R., Veena, M. S., Wang, M. B., & Srivatsan, E. S. (2011). Curcumin: a review of anti-cancer properties and therapeutic activity in head & neck squamous cell carcinoma. Molecular Cancer, 10, 12.PubMed
210.
Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21, 2895–2900.PubMed
211.
Wang, L., Shen, Y., Song, R., Sun, Y., Xu, J., & Xu, Q. (2009). An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Molecular Pharmacology, 76, 1238–1245.PubMed
212.
Wu, A. W., Basak, S. K., Lai, C., Veena, M. S., Wang, M. B., & Srivatsan, E. S. CD 44 High head and neck cancer cells demonstrate increased cell growth and chemotherapeutic resistance. In: AACR 101st Annual Meeting 2010, Washington, DC, 17–21 Apr 2010.
213.
Kakarala, M., Brenner, D. E., Korkaya, H., Cheng, C., Tazi, K., Ginestier, C., et al. (2010). Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Research and Treatment, 122, 777–785.PubMed
214.
Lim, K. J., Bisht, S., Bar, E. E., Maitra, A., & Eberhart, C. G. (2011). A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biology and Therapeutics, 11, 464–473.
215.
Kanwar, S. S., Yu, Y., Nautiyal, J., Patel, B. B., Padhye, S., Sarkar, F. H., et al. (2011). Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharmacological Research, 28, 827–838.
216.
Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., et al. (2012). Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Research, 72, 335–345.PubMed
217.
Lin, L., Liu, Y., Li, H., Li, P. K., Fuchs, J., Shibata, H., et al. (2011). Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. British Journal of Cancer, 105, 212–220.PubMed
218.
Kao, C. L., Huang, P. I., Tsai, P. H., Tsai, M. L., Lo, J. F., Lee, Y. Y., et al. (2009). Resveratrol-induced apoptosis and increased radiosensitivity in CD 133-positive cells derived from atypical teratoid/rhabdoid tumor. International Journal of Radiation Oncology, Biology, and Physics, 74, 219–228.
219.
Lu, K. H., Chen, Y. W., Tsai, P. H., Tsai, M. L., Lee, Y. Y., Chiang, C. Y., et al. (2009). Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Child’s Nervous System, 25, 543–550.PubMed
220.
Lee, D. H., Iwanski, G. B., & Thoennissen, N. H. (2010). Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal, 10, 413–418.PubMed
221.
Blaskovich, M. A., Sun, J. L., Cantor, A., Turkson, J., Jove, R., & Sebt, S. M. (2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathways inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research, 63, 1270–1279.PubMed
222.
Chen, Y. W., Chen, K. H., Huang, P. I., Chen, Y. C., Chiou, G. Y., Lo, W. L., et al. (2010). Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma–derived CD 44(+)ALDH1(+) cells. Molecular Cancer Therapeutics, 11, 2879–2892.
223.
Chang, C. J., Chiang, C. H., Song, W. S., Tsai, S. K., Woung, L. C., Chang, C. H., et al. (2012). Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nervous System, 28, 363–373.
224.
Hsu, H. S., Huang, P. I., Chang, Y. L., Tzao, C., Chen, Y. W., Shih, H. C., et al. (2011). Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD 133-positive cells. Cancer, 117, 2970–2985.PubMed
225.
Gunn, E. J., Williams, J. T., Huynh, D. T., Iannotti, M. J., Han, C., Barrios, F. J., et al. (2011). The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leukemia & Lymphoma, 52, 1085–1097.
226.
Huff, C. A., Matsui, W. H., Smith, B. D., & Jones, R. J. (2006). Strategies to eliminate cancer stem cells: clinical implications. European Journal of Cancer, 42, 1293–1297.PubMed
227.
Xu, Q., Liu, G., Yuan, X., Xu, M., Wang, H., Ji, J., et al. (2009). Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells, 27, 1734–1740.PubMed
228.
Short, J. J., & Curiel, D. T. (2009). Oncologyytic adenoviruses targeted to cancer stem cells. Molecular Cancer Therapeutics, 8, 2096–2102.PubMed
229.
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006). Targeting of CD 44 eradicates human acute myeloid leukemic stem cells. Nature Medicine, 12, 1167–1174.PubMed
230.
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., et al. (2010). Epithelial to mesenchymal transition is mechanistically linked with stem cell signature in prostate cancer cells. PLoS One, 5, e12445.PubMed
231.
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine, 17, 211–215.PubMed
232.
Uziel, T., Karginov, F. V., Xie, S., Parker, J., Wang, Y. D., Gajjar, A., et al. (2009). The miR-17 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proceedings of the National Academy of Sciences of the United States of America, 106, 2812–2817.PubMed
233.
Yu, C. C., Chen, Y. W., Chiou, G. Y., Tsai, L. L., Huang, P. I., Chang, C. Y., et al. (2011). MicroRNA let-7a represses chemo resistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncology, 47, 202–210.PubMed
234.
Lo, W. L., Yu, C. C., Chiou, G. Y., Chen, Y. W., Huang, P. I., Chien, C. S., et al. (2011). MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. The Journal of Pathology, 223, 482–495.PubMed
Metadata
Title
Cancer stem cells, microRNAs, and therapeutic strategies including natural products
Authors
Darshni Vira
Saroj K. Basak
Mysore S. Veena
Marilene B. Wang
Raj K. Batra
Eri S. Srivatsan
Publication date
01-12-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9382-8

Other articles of this Issue 3-4/2012

Cancer and Metastasis Reviews 3-4/2012 Go to the issue

OriginalPaper

Raf kinase inhibitor protein (RKIP) in cancer

NON-THEMATIC REVIEW

Metastatic view of breast cancer

OriginalPaper

Genes associate with abnormal bone cell activity in bone metastasis

NON-THEMATIC REVIEW

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

OriginalPaper

The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis

OriginalPaper

MDM2 binding protein, a novel metastasis suppressor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits